Characteristics of patients infused with tisa-cel and postinfusion CRS
| Variables . | . | No. (n = 25) . |
|---|---|---|
| Infused tisa-cel | ||
| Total viable cell number | Median (range), ×109 | 1.0 (0.2-2.3) |
| Total number of tisa-cel | Median (range), ×108 | 3.0 (0.8-4.5) |
| IFN-γ expression | Median (range), fg per transduced cell | 74 (37-346) |
| CRS | ||
| Grade | 0/1/2 | 1 (4%)/20 (80%)/4 (16%) |
| Duration, d | Median (range) | 8 (5-21) |
| Tocilizumab | ||
| Administration | Yes | 13 (52%) |
| Number of doses | 1/2/3/4 | 8 (62%)/3 (23%)/0 (0%)/2 (15%) |
| Variables . | . | No. (n = 25) . |
|---|---|---|
| Infused tisa-cel | ||
| Total viable cell number | Median (range), ×109 | 1.0 (0.2-2.3) |
| Total number of tisa-cel | Median (range), ×108 | 3.0 (0.8-4.5) |
| IFN-γ expression | Median (range), fg per transduced cell | 74 (37-346) |
| CRS | ||
| Grade | 0/1/2 | 1 (4%)/20 (80%)/4 (16%) |
| Duration, d | Median (range) | 8 (5-21) |
| Tocilizumab | ||
| Administration | Yes | 13 (52%) |
| Number of doses | 1/2/3/4 | 8 (62%)/3 (23%)/0 (0%)/2 (15%) |
IFN-γ, interferon-γ.